C4 Therapeutics (NASDAQ:CCCC) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of C4 Therapeutics (NASDAQ:CCCC) from a strong sell rating to a hold rating in a research note published on Saturday morning.

A number of other research firms have also recently commented on CCCC. Brookline Capital Acquisition upped their price target on C4 Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Barclays boosted their price objective on C4 Therapeutics from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Thursday. TD Cowen restated a “buy” rating on shares of C4 Therapeutics in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Wednesday, January 21st. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.20.

C4 Therapeutics Price Performance

NASDAQ CCCC opened at $2.70 on Friday. The stock has a market capitalization of $261.66 million, a P/E ratio of -1.99 and a beta of 2.96. The firm’s 50-day moving average is $2.09 and its two-hundred day moving average is $2.36. C4 Therapeutics has a 12 month low of $1.09 and a 12 month high of $3.65.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.25. The business had revenue of $11.02 million for the quarter, compared to the consensus estimate of $4.48 million. C4 Therapeutics had a negative net margin of 292.08% and a negative return on equity of 60.16%. As a group, analysts anticipate that C4 Therapeutics will post -1.52 EPS for the current year.

Institutional Trading of C4 Therapeutics

A number of institutional investors have recently bought and sold shares of CCCC. Zacks Investment Management acquired a new position in shares of C4 Therapeutics during the 3rd quarter worth about $29,000. Dynamic Technology Lab Private Ltd purchased a new stake in C4 Therapeutics during the second quarter worth approximately $31,000. Delta Investment Management LLC acquired a new position in C4 Therapeutics in the fourth quarter valued at approximately $38,000. Savant Capital LLC purchased a new position in C4 Therapeutics in the second quarter valued at approximately $38,000. Finally, Virtu Financial LLC purchased a new position in C4 Therapeutics in the fourth quarter valued at approximately $39,000. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.